| CAS: | 95233-18-4 |
| MF: | C22H19ClO3 |
| MW: | 366.84 |
| EINECS: | 000-000-0 |
| Product Categories: | Intermediates & Fine Chemicals;Pharmaceuticals;Heterocycles;LEVATOL |
| Mol File: | 95233-18-4.mol |
 |
|
| Atovaquone Chemical Properties |
| Melting point | 216-2190C |
| Boiling point | 535.0±50.0 °C(Predicted) |
| density | 1.349±0.06 g/cm3(Predicted) |
| storage temp. | 2-8°C |
| solubility | DMSO: >10mg/mL |
| form | powder |
| pka | 5.01±0.10(Predicted) |
| color | yellow |
| λmax | 494nm(aq. Buffer)(lit.) |
| Merck | 14,866 |
| InChIKey | KUCQYCKVKVOKAY-CTYIDZIISA-N |
| CAS DataBase Reference | 95233-18-4(CAS DataBase Reference) |
| Atovaquone Usage And Synthesis |
| Antimalarial Agent | The hydroxynaphthoquinone atovaquone, which exhibits antimalarial and anti-Pneumocystis activity, is an electron transport inhibitor that causes depletion of the ATP pool. The primary effect is on the iron flavoprotein dihydro-orotate dehydrogenase, an essential enzyme in the production of pyrimidines. Mammalian cells are able to avoid undue toxicity by use of preformed pyrimidines. Dihydro-orotate dehydrogenase from Plasmodium falciparum is inhibited by concentrations of atovaquone that are very much lower than those needed to inhibit the Pneumocystis enzyme, raising the possibility that the antimicrobial consequences might differ in the two organisms. Although atovaquone was originally developed as a monotherapy for malaria, high level resistance readily emerges in Plasmodium falciparum when the drug is used alone. Consequently, atovaquone is now combined with proguanil. |
| Description | Atovaquone is an orally active antiprotozoal agent indicated for patients with mild to moderate AIDS-associated Pneumocystis carinii pneumonia who are intolerant to the fist-line therapy of trimethoprim-sulfamethoxazole. It is also under investigation as a treatment for malaria and AIDS-associated toxoplasmosis. |
| Chemical Properties | Yellow to Orange Crystalline Solid |
| Originator | Wellcome (United Kingdom) |
| Uses | Hydroxynaphthoquinone derivative that inhibits mitochondrial electron transport. Antipneumocystic |
| Uses | beta-adrenergic blocker |
| Uses | Atovaquone inhibits the cytochrome bc(1) complex via interactions with the Rieske iron-sulfur protein and cytochrome b in the ubiquinol oxidation pocket. In addition to its use as a treatment for toxoplasmosis, atovaquone has antimalarial properties and prevents pneumocystis pneumonia post-renal transplant. |
Product picture
Packing &shipping&Payment
Packing:25kg/drum
Shipping:by sea or by air
Payment:T/T,western union,moneygram
Packaging Details drum
Port:Tianjin
Lead Time :
| Quantity(Kilograms) | 1 - 10000 | >10000 |
| Est. Time(days) | 5 | To be negotiated |
Company information
Hebei Mojin Biotechnology Co., Ltd, Our company is a professional in 4'-Methylacetophenone,Levamisole hydrochloride ,N-Methylformamide and other chemical reagents research and development production enterprises. Our business covers more than 30 countries, most of the big customers come from Europe, America and other countries in the world, we can guarantee the quality and price. In recent decades, with the efforts of all employees, we have established many cooperative companies in shandong, henan, guangdong and other places. Our corporate purpose is based on the market, enhance the strength, take the road of scientific and environmental sustainable development, relying on the country. Technology r & d center, increase the investment in r & d, based on the domestic market, expand the international market, manufacturing quality products, sincere service to the society, into a modern, ecological, scientific and technological enterprise world.
Advantage
In stock
Japan
